Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam B Shapiro

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|December 15, 2020
<i>In Vitro</i> Antibacterial Activity and <i>In Vivo</i> Efficacy of Sulbactam-Durlobactam against Pathogenic <i>Burkholderia</i> SpeciesKrisztina M Papp-Wallace, Adam B Shapiro, Scott A Becka, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2010
Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivoScott D Mills, Ann E Eakin, Ed T Buurman, et al.
Antimicrobial Agents and Chemotherapy|January 7, 2015
Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumanniiWilliam F Penwell, Adam B Shapiro, Robert A Giacobbe, et al.
The Journal of Biological Chemistry|July 8, 2015
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914Gunther Kern, Tiffany Palmer, David E Ehmann, et al.
The Journal of Biological Chemistry|June 18, 2014
The role of a novel auxiliary pocket in bacterial phenylalanyl-tRNA synthetase druggabilityAyome Abibi, Andrew D Ferguson, Paul R Fleming, et al.
Current Topics in Medicinal Chemistry|November 6, 2007
An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmesJeffrey S Albert, Niklas Blomberg, Alexander L Breeze, et al.
Bioorganic & Medicinal Chemistry|November 7, 2020
N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assayTakeru Furuya, Adam B Shapiro, Janelle Comita-Prevoir, et al.
Journal of Medicinal Chemistry|July 14, 2020
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-LactamasesThomas F Durand-Réville, Janelle Comita-Prevoir, Jing Zhang, et al.
Journal of Medicinal Chemistry|February 7, 2015
Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic modelKerry E Murphy-Benenato, Pratik R Bhagunde, April Chen, et al.
Nature Microbiology|July 1, 2017
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiThomas F Durand-Réville, Satenig Guler, Janelle Comita-Prevoir, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|December 15, 2020
<i>In Vitro</i> Antibacterial Activity and <i>In Vivo</i> Efficacy of Sulbactam-Durlobactam against Pathogenic <i>Burkholderia</i> SpeciesKrisztina M Papp-Wallace, Adam B Shapiro, Scott A Becka, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2010
Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivoScott D Mills, Ann E Eakin, Ed T Buurman, et al.
Antimicrobial Agents and Chemotherapy|January 7, 2015
Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumanniiWilliam F Penwell, Adam B Shapiro, Robert A Giacobbe, et al.
The Journal of Biological Chemistry|July 8, 2015
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914Gunther Kern, Tiffany Palmer, David E Ehmann, et al.
The Journal of Biological Chemistry|June 18, 2014
The role of a novel auxiliary pocket in bacterial phenylalanyl-tRNA synthetase druggabilityAyome Abibi, Andrew D Ferguson, Paul R Fleming, et al.
Current Topics in Medicinal Chemistry|November 6, 2007
An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmesJeffrey S Albert, Niklas Blomberg, Alexander L Breeze, et al.
Bioorganic & Medicinal Chemistry|November 7, 2020
N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assayTakeru Furuya, Adam B Shapiro, Janelle Comita-Prevoir, et al.
Journal of Medicinal Chemistry|July 14, 2020
Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-LactamasesThomas F Durand-Réville, Janelle Comita-Prevoir, Jing Zhang, et al.
Journal of Medicinal Chemistry|February 7, 2015
Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic modelKerry E Murphy-Benenato, Pratik R Bhagunde, April Chen, et al.
Nature Microbiology|July 1, 2017
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiThomas F Durand-Réville, Satenig Guler, Janelle Comita-Prevoir, et al.
Pageof 6